Exome Asset Management’s Lipocine LPCN Stock Holding History

Exome Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60,861	Closed	-$486K	–	62
2026 Q1	$486K	Buy	+60,861	New	+$530K	0.25%	53

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Exome Asset Management's LPCN Position: Q2 2026 in Review

Exome Asset Management sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 60,861 shares — an estimated $486K sold.

Exome Asset Management first reported a position in LPCN in Q1 2026 and held it in 1 quarter. The position peaked at $486K in Q1 2026. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Exome Asset Management reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
Exome Asset Management sold 60,861 Lipocine shares in Q2 2026, an estimated $486K.
Exome Asset Management first reported a position in Lipocine in Q1 2026 and held it in 1 quarter.
Exome Asset Management's Lipocine position peaked at $486K in Q1 2026.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.